Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04703192

Recruitment Status : Active, not recruiting

First Posted : January 11, 2021

Last Update Posted : April 15, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Daiichi Sankyo

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	May 10, 2023
Estimated Study Completion Date :	September 8, 2025

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	May 10, 2024

To Top